In patients with CLL, this increase was slightly lower than in patients with CVID and was, respectively: 2.24-fold for CD4+TLR3+, 2.39-fold for CD8+TLR3+, and 5.38-fold for CD19+TLR3+ (Figure 5) (Table 3). This evidence concerns the gene TLR3 and common variable immunodeficiency.